Metabolism as a biomarker for treatment success in anti-amyloid therapy: A case report

Q4 Neuroscience

Neuroimage. Reports Pub Date : 2024-04-27 DOI:10.1016/j.ynirp.2024.100203

Kirk C. Wilhelmsen , Pierre-François D’Haese , Marc W. Haut , Gary D. Marano , Rashi I. Mehta , Xiaofei Wang , Melanie Ward , Mark Miller , Umer Najib , R. Osvaldo Navia , Cierra M. Keith , Ali Rezai

{"title":"Metabolism as a biomarker for treatment success in anti-amyloid therapy: A case report","authors":"Kirk C. Wilhelmsen , Pierre-François D’Haese , Marc W. Haut , Gary D. Marano , Rashi I. Mehta , Xiaofei Wang , Melanie Ward , Mark Miller , Umer Najib , R. Osvaldo Navia , Cierra M. Keith , Ali Rezai","doi":"10.1016/j.ynirp.2024.100203","DOIUrl":null,"url":null,"abstract":"<div><p>This case report investigates the potential use of metabolism as a sensitive biomarker in monitoring the effectiveness of anti-amyloid therapy in a patient with mild cognitive impairment due to early Alzheimer's disease. The study centers around a 74-year-old male patient treated with aducanumab, a monoclonal antibody developed for anti-amyloid therapy. Alongside an expected decline in cerebral amyloid monitored using PET amyloid tracers, we observed significant improvements in the patient's brain metabolic activity, measured via 18-fluorodeoxyglucose positron emission tomography (FDG PET). Despite limitations posed by the single-patient case study, the findings invite further research and consider the utilization of FDG PET as a surrogate for clinically meaningful changes in the treatment of early Alzheimer's disease. These findings suggest the potential for more personalized and effective therapeutic interventions.</p></div>","PeriodicalId":74277,"journal":{"name":"Neuroimage. Reports","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666956024000096/pdfft?md5=75b759aca7a14017053f665c49e8fb5f&pid=1-s2.0-S2666956024000096-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroimage. Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666956024000096","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Neuroscience","Score":null,"Total":0}

引用次数: 0

Abstract

This case report investigates the potential use of metabolism as a sensitive biomarker in monitoring the effectiveness of anti-amyloid therapy in a patient with mild cognitive impairment due to early Alzheimer's disease. The study centers around a 74-year-old male patient treated with aducanumab, a monoclonal antibody developed for anti-amyloid therapy. Alongside an expected decline in cerebral amyloid monitored using PET amyloid tracers, we observed significant improvements in the patient's brain metabolic activity, measured via 18-fluorodeoxyglucose positron emission tomography (FDG PET). Despite limitations posed by the single-patient case study, the findings invite further research and consider the utilization of FDG PET as a surrogate for clinically meaningful changes in the treatment of early Alzheimer's disease. These findings suggest the potential for more personalized and effective therapeutic interventions.

查看原文本刊更多论文

代谢作为抗淀粉样蛋白治疗成功与否的生物标志物：病例报告

本病例报告调查了代谢作为一种敏感的生物标志物在监测因早期阿尔茨海默病导致轻度认知障碍的患者的抗淀粉样蛋白治疗效果方面的潜在用途。研究围绕一名 74 岁的男性患者展开，患者接受了阿杜卡单抗治疗，这是一种用于抗淀粉样蛋白治疗的单克隆抗体。在使用正电子发射计算机断层扫描（PET）淀粉样蛋白示踪剂监测脑淀粉样蛋白预期下降的同时，我们还通过18-氟脱氧葡萄糖正电子发射计算机断层扫描（FDG PET）观察到患者大脑代谢活动的显著改善。尽管单个患者病例研究存在局限性，但研究结果仍值得进一步研究，并考虑在治疗早期阿尔茨海默病时将 FDG PET 用作具有临床意义变化的替代物。这些研究结果表明，我们有可能采取更加个性化和有效的治疗干预措施。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neuroimage. Reports Neuroscience (General)

CiteScore

1.90

自引率

0.00%

发文量

审稿时长

87 days